Cidara Therapeutics (NASDAQ:CDTX – Get Rating) and Microbot Medical (NASDAQ:MBOT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Insider & Institutional Ownership
58.2% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Microbot Medical shares are held by institutional investors. 8.0% of Cidara Therapeutics shares are held by insiders. Comparatively, 10.8% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Cidara Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 3.83, meaning that its share price is 283% more volatile than the S&P 500.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cidara Therapeutics presently has a consensus price target of $6.45, suggesting a potential upside of 783.56%. Given Cidara Therapeutics’ higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Microbot Medical.
This table compares Cidara Therapeutics and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Cidara Therapeutics and Microbot Medical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cidara Therapeutics||$49.57 million||1.02||-$42.47 million||($0.72)||-1.01|
|Microbot Medical||N/A||N/A||-$11.31 million||($1.42)||-3.49|
Microbot Medical has lower revenue, but higher earnings than Cidara Therapeutics. Microbot Medical is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cidara Therapeutics beats Microbot Medical on 7 of the 13 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.